Matthieu Simon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Matthieu Simon has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Krzysztof Rogowski
Institute of Human Genetics
2 shared publications - Lubomir L. Vezenkov
IBMM Université Montpellier, CNRS, ENSCM Montpellier France
2 shared publications Marie Maumus
Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB) (Institute for Regenerative Medicine and Biotherapy - 80 rue Augustin Fliche 34295 Montpellier - Cedex 5 - France)
2 shared publications- Muriel Amblard
IBMM UMR5247 Univ. Montpellier CNRS ENSCM Montpellier France
2 shared publications Ahmad Medhi
ICGM
1 shared publication- Anthony Feral
IBMM (Institut des Biomolécules Max Mousseron), Amino Acids, Peptides and Proteins department, Université de Montpellier, CNRS, Ecole Nationale Supérieure de Chimie de Montpellier
1 shared publication
Latest Publications
- Open Access
- 31 December 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (1)
Peptide-based covalent inhibitor of tubulin detyrosination promotes mesenchymal-to-epithelial transition in lung cancer cells
Detyrosination is a reversible posttranslational modification specific to α-tubulin, which has been implicated in cancer progression and invasiveness by promoting epithelial-to-mesenchymal transition. The members of the vasohibin family, VASH1 and VASH2, were previously identified as the first class of enzymes involved in catalyzing this modification. Here, we report the development of a covalent VASH inhibitor, which is characterized by high specificity and low toxicity. By combining the use of a new compound with molecular approaches in lung cancer cell lines, we find that tubulin detyrosination plays an important role in the maintenance of mesenchymal properties. We show that in the absence of VASH activity, collective cell migration and 3D spheroid formation are severely compromised. Moreover, we demonstrate that the observed phenotypes are caused by the accumulation of the important epithelial marker E-cadherin with simultaneous reduction in mesenchymal markers N-cadherin and vimentin. Taken together, our study establishes tubulin detyrosination as a promising target for the future development of anticancer treatment.
- 31 December 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (1)
Open AccessPeptide-based covalent inhibitor of tubulin detyrosination promotes mesenchymal-to-epithelial transition in lung cancer cells
Detyrosination is a reversible posttranslational modification specific to α-tubulin, which has been implicated in cancer progression and invasiveness by promoting epithelial-to-mesenchymal transition. The members of the vasohibin family, VASH1 and VASH2, were previously identified as the first class of enzymes involved in catalyzing this modification. Here, we report the development of a covalent VASH inhibitor, which is characterized by high specificity and low toxicity. By combining the use of a new compound with molecular approaches in lung cancer cell lines, we find that tubulin detyrosination plays an important role in the maintenance of mesenchymal properties. We show that in the absence of VASH activity, collective cell migration and 3D spheroid formation are severely compromised. Moreover, we demonstrate that the observed phenotypes are caused by the accumulation of the important epithelial marker E-cadherin with simultaneous reduction in mesenchymal markers N-cadherin and vimentin. Taken together, our study establishes tubulin detyrosination as a promising target for the future development of anticancer treatment.
- Open Access
- 12 November 2025
- Published by Wiley in Protein Science
- Vol. 34 (12) , e70374
Real‐time FRET assay for monitoring detyrosination by TMCP1 and VASH2
Tubulin detyrosination is an important α‐tubulin specific posttranslational modification which has been implicated in various disorders including neurodegeneration and cancer. As such, the enzymes involved in the generation of this modification emerged as promising therapeutic targets. Previous studies have identified the members of the vasohibin family, VASH1 and VASH2, as the first class of enzymes involved in the generation of detyrosination. Recently, we have discovered Tubulin MetalloCarboxyPeptidase 1 (TMCP1) as the second class of enzymes catalyzing this modification. Here we describe the development of a highly sensitive FRET‐based enzymatic assay to study and monitor the activity of TMCP1 and VASH2. The originality of this assay lies in the use of 3‐nitrotyrosine as a quencher, which not only restores fluorescence upon cleavage but also closely mimics the natural tyrosine substrate, ensuring optimal enzyme recognition. The selected fluorogenic substrate, named FS2, exhibited strong quenching efficiency and a high signal‐to‐noise ratio, allowing for real‐time kinetic monitoring of TMCP1 and VASH2 activity. Enzyme kinetics, competition assays, and metal ion dependency studies confirmed the assay's specificity, robustness, and physiological relevance. This optimized assay provides a powerful and reliable tool for the future identification and characterization of inhibitors of α‐tubulin detyrosination.
- 12 November 2025
- Published by Wiley in Protein Science
- Vol. 34 (12) , e70374
Open AccessReal‐time FRET assay for monitoring detyrosination by TMCP1 and VASH2
Tubulin detyrosination is an important α‐tubulin specific posttranslational modification which has been implicated in various disorders including neurodegeneration and cancer. As such, the enzymes involved in the generation of this modification emerged as promising therapeutic targets. Previous studies have identified the members of the vasohibin family, VASH1 and VASH2, as the first class of enzymes involved in the generation of detyrosination. Recently, we have discovered Tubulin MetalloCarboxyPeptidase 1 (TMCP1) as the second class of enzymes catalyzing this modification. Here we describe the development of a highly sensitive FRET‐based enzymatic assay to study and monitor the activity of TMCP1 and VASH2. The originality of this assay lies in the use of 3‐nitrotyrosine as a quencher, which not only restores fluorescence upon cleavage but also closely mimics the natural tyrosine substrate, ensuring optimal enzyme recognition. The selected fluorogenic substrate, named FS2, exhibited strong quenching efficiency and a high signal‐to‐noise ratio, allowing for real‐time kinetic monitoring of TMCP1 and VASH2 activity. Enzyme kinetics, competition assays, and metal ion dependency studies confirmed the assay's specificity, robustness, and physiological relevance. This optimized assay provides a powerful and reliable tool for the future identification and characterization of inhibitors of α‐tubulin detyrosination.
- 11 November 2022
- Published by Elsevier in Bioprinting
- Vol. 28, e00253
3D bioprinting of articular cartilage: Recent advances and perspectives
- 11 November 2022
- Published by Elsevier in Bioprinting
- Vol. 28, e00253
3D bioprinting of articular cartilage: Recent advances and perspectives
- Open Access
- 16 June 2022
- Published by American Chemical Society (ACS) in ChemRxiv
Gelatin modified with alkoxysilanes (GelmSi) forms hybrid hydrogels for bioengineering applications
Biopolymers are ideal candidates for the development of hydrogels for tissue engineering applications. However, chemical modifications are required to further improve their mechanical properties, in particular to cross-link them for long-lasting applications or biofabrication. Herein, we developed a novel gelatin-based hydrogel precursor, “GelmSi”. Gelatin was chosen as starting material because of its biocompatibility and bioactivity, favouring cell adhesion and migration. Alkoxysilane moieties were introduced in a controlled manner on the lysine side chains of gelatin to obtain a hybrid precursor which reacts in physiological conditions, forming covalent siloxane bonds and allowing the formation of a three-dimensional chemical network. On the contrary to unmodified gelatin, siloxane covalent network dramatically increases the stiffness and the thermal stability of the resulting gelatin-based hydrogel, making it suitable for cell encapsulation and cell culture. The biorthogonality and versatility of the GelmSi hybrid hydrogel unlock a broad range of gelatin-based bioengineering applications.
- 16 June 2022
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessGelatin modified with alkoxysilanes (GelmSi) forms hybrid hydrogels for bioengineering applications
Biopolymers are ideal candidates for the development of hydrogels for tissue engineering applications. However, chemical modifications are required to further improve their mechanical properties, in particular to cross-link them for long-lasting applications or biofabrication. Herein, we developed a novel gelatin-based hydrogel precursor, “GelmSi”. Gelatin was chosen as starting material because of its biocompatibility and bioactivity, favouring cell adhesion and migration. Alkoxysilane moieties were introduced in a controlled manner on the lysine side chains of gelatin to obtain a hybrid precursor which reacts in physiological conditions, forming covalent siloxane bonds and allowing the formation of a three-dimensional chemical network. On the contrary to unmodified gelatin, siloxane covalent network dramatically increases the stiffness and the thermal stability of the resulting gelatin-based hydrogel, making it suitable for cell encapsulation and cell culture. The biorthogonality and versatility of the GelmSi hybrid hydrogel unlock a broad range of gelatin-based bioengineering applications.